Document Detail


Long-term trends in adherence to antiretroviral therapy from start of HAART.
MedLine Citation:
PMID:  20299959     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: People on antiretroviral therapy are likely to be required to maintain good adherence throughout their lives. We aimed to investigate long-term trends in highly active antiretroviral therapy (HAART) adherence to identify the main predictors and to evaluate whether participants experience periods of low adherence (<or=60%).
METHODS: Participants in the Royal Free Clinic Cohort were followed from the date of start of HAART until the end of the last recorded ART prescription or death. Follow-up was divided into 6-month periods, and for each period, a value of adherence, measured as the percentage of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs, was calculated.
RESULTS: Patients were assessed for drug coverage adherence for a median of 4.5 years [inter-quartile range (IQR) 2.4-7.2; maximum 9 years] covering a period up to 13 years from start of HAART. There was evidence of a slight increase in adherence over time [adjusted odds ratio (OR) of >95% adherence = 1.02 per year; 95% confidence interval (CI) 1.01-1.04; P = 0.0053]. Independent predictors of adherence were age, demographic group, calendar year period, drug regimen and previous virologic failures. The overall rate of at least one period of low adherence was 0.12 per person-year, but this rate decrease markedly over time to 0.01 in 2007/2008.
CONCLUSION: Adherence, as measured by drug coverage, does not decrease on average over more than a decade from start of HAART. This is encouraging, because it shows that patients could potentially maintain viral suppression for many years.
Authors:
Valentina Cambiano; Fiona C Lampe; Alison J Rodger; Colette J Smith; Anna M Geretti; Rebecca K Lodwick; Dewi I Puradiredja; Margaret Johnson; Leonie Swaden; Andrew N Phillips
Related Documents :
8359619 - Long-term therapeutic efficacy of interferon for patients with chronic hepatitis c.
14720449 - Guidelines for stopping therapy in chronic hepatitis c.
19812449 - Efficacy and safety of darunavir/ritonavir in treatment-experienced hiv type-1 patients...
16753449 - Single-blind, multicenter, placebo controlled, parallel study to assess the safety and ...
20624069 - Immune reconstitution in severely immunosuppressed antiretroviral-naive hiv type 1-infe...
9651559 - Efficacy and safety of systemic recombinant interferon-alpha in behçet's disease.
19832909 - A novel approach to controlling bacterial contamination on toothbrushes: chlorhexidine ...
19618979 - Composition of the council of representatives: report on the apportionment ballot for r...
10083629 - Endoscopic treatment of complete posterior urethral obliteration.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS (London, England)     Volume:  24     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  1153-62     Citation Subset:  IM; X    
Affiliation:
HIV Epidemiology & Biostatistics Group, Research Department of Infection & Population Health, UCL Medical School, Royal Free Campus, London, UK. v.cambiano@ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy...
Next Document:  An insight into the opening path to semi-open conformation of HIV-1 protease by molecular dynamics s...